Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
J Travel Med. 2006 Mar-Apr; 13(2):78-83.JT

Abstract

BACKGROUND

Protection against hepatitis A virus (HAV) in the elderly is becoming more important as more senior travelers visit areas of high HAV endemicity, and less have protective antibodies acquired after natural infection during childhood. This study assessed the immunogenicity and safety of hepatitis A vaccine in elderly compared to young adults.

METHODS

In this open, uncontrolled study, subjects of 18 to 45 years or < or = 50 years of age received two doses of aluminum-free, virosomal HAV vaccine, Epaxal (Berna Biotech Ltd, formerly Swiss Serum and Vaccine Institute, Bern, Switzerland) 12 months apart.

RESULTS

After both the basic and the booster doses, geometric mean titers (GMT) for anti-HAV antibodies were 1.7-fold higher in subjects younger than 45 years compared with those < or = 50 years of age. The proportional increase in GMT after the booster dose, however, was similar in younger and older subjects. Seroprotection (< or = 20 mIU/mL) rates in the younger and older subjects were 100 and 65%, respectively, after the first vaccination and 100 and 97%, respectively, after the booster dose. Systemic and local adverse events were mainly mild and short-lived.

CONCLUSION

These data show that HAV virosomal vaccine (Epaxal) is well tolerated and immunogenic in elderly subjects. The clinical relevance of lower seroconversion rates after the primary dose is unknown in this population of travelers.

Authors+Show Affiliations

Medical Outpatient Clinic, University Hospital, Lausanne, Switzerland.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16553593

Citation

D'Acremont, Valérie, et al. "Immunogenicity and Safety of a Virosomal Hepatitis a Vaccine (Epaxal) in the Elderly." Journal of Travel Medicine, vol. 13, no. 2, 2006, pp. 78-83.
D'Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med. 2006;13(2):78-83.
D'Acremont, V., Herzog, C., & Genton, B. (2006). Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. Journal of Travel Medicine, 13(2), 78-83.
D'Acremont V, Herzog C, Genton B. Immunogenicity and Safety of a Virosomal Hepatitis a Vaccine (Epaxal) in the Elderly. J Travel Med. 2006 Mar-Apr;13(2):78-83. PubMed PMID: 16553593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. AU - D'Acremont,Valérie, AU - Herzog,Christian, AU - Genton,Blaise, PY - 2006/3/24/pubmed PY - 2006/5/23/medline PY - 2006/3/24/entrez SP - 78 EP - 83 JF - Journal of travel medicine JO - J Travel Med VL - 13 IS - 2 N2 - BACKGROUND: Protection against hepatitis A virus (HAV) in the elderly is becoming more important as more senior travelers visit areas of high HAV endemicity, and less have protective antibodies acquired after natural infection during childhood. This study assessed the immunogenicity and safety of hepatitis A vaccine in elderly compared to young adults. METHODS: In this open, uncontrolled study, subjects of 18 to 45 years or < or = 50 years of age received two doses of aluminum-free, virosomal HAV vaccine, Epaxal (Berna Biotech Ltd, formerly Swiss Serum and Vaccine Institute, Bern, Switzerland) 12 months apart. RESULTS: After both the basic and the booster doses, geometric mean titers (GMT) for anti-HAV antibodies were 1.7-fold higher in subjects younger than 45 years compared with those < or = 50 years of age. The proportional increase in GMT after the booster dose, however, was similar in younger and older subjects. Seroprotection (< or = 20 mIU/mL) rates in the younger and older subjects were 100 and 65%, respectively, after the first vaccination and 100 and 97%, respectively, after the booster dose. Systemic and local adverse events were mainly mild and short-lived. CONCLUSION: These data show that HAV virosomal vaccine (Epaxal) is well tolerated and immunogenic in elderly subjects. The clinical relevance of lower seroconversion rates after the primary dose is unknown in this population of travelers. SN - 1195-1982 UR - https://www.unboundmedicine.com/medline/citation/16553593/Immunogenicity_and_safety_of_a_virosomal_hepatitis_A_vaccine__Epaxal__in_the_elderly_ L2 - https://academic.oup.com/jtm/article-lookup/doi/10.1111/j.1708-8305.2006.00001.x DB - PRIME DP - Unbound Medicine ER -